Atomically accurate de novo design of antibodies with RFdiffusion.
Bennett Nathaniel R, Watson Joseph L, Ragotte Robert J, Borst Andrew J, See DéJenaé L, Weidle Connor, Biswas Riti, Yu Yutong, Shrock Ellen L, Ault Russell, Leung Philip J Y, Huang Buwei, Goreshnik Inna, Tam John, Carr Kenneth D, Singer Benedikt, Criswell Cameron, Wicky Basile I M, Vafeados Dionne, Garcia Sanchez Mariana, Kim Ho Min, Vázquez Torres Susana, Chan Sidney, Sun Shirley M, Spear Timothy T, Sun Yi, O'Reilly Keelan, Maris John M, Sgourakis Nikolaos G, Melnyk Roman A, Liu Chang C, Baker David
Nature · 2026 · PMID 41193805 · 인용 102
Despite the central role of antibodies in modern medicine, no method currently exists to design novel, epitope-specific antibodies entirely in silico. Instead, antibody discovery currently relies on immunization, random library screening or the isolation of antibodies directly from patients1. Here we demonstrate that combining computational protein design using a fine-tuned RFdiffusion2 network with yeast display screening enables the de novo generation of antibody variable heavy chains (VHHs), single-chain variable fragments (scFvs) and full antibodies that bind to user-specified epitopes with atomic-level precision.
We experimentally characterize VHH binders to four disease-relevant epitopes. Cryo-electron microscopy confirms the binding pose of designed VHHs targeting influenza haemagglutinin and Clostridium difficile toxin B (TcdB). A high-resolution structure of the influenza-targeting VHH confirms atomic accuracy of the designed complementarity-determining regions (CDRs).
Although initial computational designs exhibit modest affinity (tens to hundreds of nanomolar Kd), affinity maturation using OrthoRep3 enables production of single-digit nanomolar binders that maintain the intended epitope selectivity. We further demonstrate the de novo design of scFvs to TcdB and a PHOX2B peptide-MHC complex by combining designed heavy-chain and light-chain CDRs. Cryo-electron microscopy confirms the binding pose for two distinct TcdB scFvs, with high-resolution data for one design verifying the atomically accurate design of the conformations of all six CDR loops.
Our approach establishes a framework for the computational design, screening and characterization of fully de novo antibodies with atomic-level precision in both structure and epitope targeting.